ストックスクリーナーアプリを入手
44.47
0.47%
0.21
プレマーケット:
44.47
前日終値:
$44.26
開ける：
$44.29
24時間の取引高:
2.28M
Relative Volume:
0.72
時価総額：
$12.13B
収益：
$2.17B
当期純損益:
$521.27M
株価収益率:
25.12
EPS:
1.77
ネットキャッシュフロー:
$633.79M
1週間 パフォーマンス:
+0.93%
1か月 パフォーマンス:
+10.16%
6か月 パフォーマンス:
+35.25%
1年 パフォーマンス:
+96.77%
1日の値動き範囲:
$43.86
$44.84
1週間の範囲:
$43.86
$45.52
52週間の値動き範囲:
$22.20
$49.62
Exelixis Inc Stock (EXEL) Company Profile
EXEL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.47 | 12.02B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2024-09-19 | 開始されました | UBS | Neutral |
| 2024-04-11 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 開始されました | BTIG Research | Buy |
| 2023-12-15 | 開始されました | Citigroup | Buy |
| 2023-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-22 | 繰り返されました | Oppenheimer | Outperform |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 再開されました | Piper Sandler | Overweight |
| 2023-03-09 | 開始されました | Wells Fargo | Overweight |
| 2023-01-26 | 開始されました | Credit Suisse | Outperform |
| 2022-10-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-11-03 | 再開されました | Jefferies | Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-18 | 再開されました | Goldman | Sell |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-03-18 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 開始されました | Goldman | Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Underweight |
| 2018-05-11 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-16 | 繰り返されました | SunTrust | Buy |
| 2017-09-22 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-09-12 | 繰り返されました | Needham | Buy |
| 2017-07-14 | 開始されました | SunTrust | Buy |
| 2017-03-31 | 開始されました | Needham | Buy |
| 2017-03-16 | 開始されました | Oppenheimer | Perform |
| 2017-02-28 | ダウングレード | Stifel | Buy → Hold |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2016-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 繰り返されました | Stifel | Buy |
すべてを表示
Exelixis Inc (EXEL) 最新ニュース
Is Exelixis Inc. a good long term investmentSuperior profit margins - jammulinksnews.com
Is Exelixis, Inc.'s (NASDAQ:EXEL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Yahoo Finance
Lobbying Update: $480,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative
What analysts say about Exelixis Inc. stockStrong return on investment - Autocar Professional
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Exelixis Inc. Stock Analysis and ForecastTremendous wealth creation - PrintWeekIndia
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner - The Motley Fool
What drives Exelixis Inc. stock priceHigh-performance investment picks - jammulinksnews.com
Teva Pharmaceutical Industries Limited shares fall 1.38% intraday after Exelixis, Inc. presents at Lucid Capital Markets. - AInvest
Exelixis Advances Cancer Treatment with New Phase 1 Study of XL309 - The Globe and Mail
Exelixis’s SWOT analysis: zanza trials key to stock’s future growth By Investing.com - Investing.com South Africa
Exelixis’s SWOT analysis: zanza trials key to stock’s future growth - Investing.com
Exelixis Insiders Sell US$12m Of Stock, Possibly Signalling Caution - simplywall.st
Long Term Trading Analysis for (EXEL) - news.stocktradersdaily.com
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - The Globe and Mail
Truist Securities raises Exelixis stock price target to $56 on positive outlook - Investing.com Canada
Truist Lifts Price Target on Exelixis to $56 From $55, Keeps Buy Rating - MarketScreener
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - BioSpace
Press Release: Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - 富途牛牛
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why - sharewise.com
Exelixis’ Phase 3 Trial: A New Hope for Renal Cell Carcinoma? - TipRanks
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and Exelixis (EXEL) - The Globe and Mail
Barclays Remains a Hold on Exelixis (EXEL) - The Globe and Mail
Assessing Exelixis: Insights From 12 Financial Analysts - Nasdaq
Exelixis cut to sector perform at RBC as cash flows fairly valued - MSN
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance
RBC Capital Keeps Their Buy Rating on Exelixis (EXEL) - The Globe and Mail
RBC Downgrades Exelixis to Sector Perform From Outperform, Lifts Price Target to $50 From $45 - MarketScreener
Exelixis (EXEL): Why Now is the Time to Act on Strong Clinical and Financial Catalysts - AInvest
Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade) - Seeking Alpha
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock? - The Globe and Mail
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Exelixis’s SWOT analysis: stock poised for growth amid pipeline progress - Investing.com
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore - Yahoo Finance
Cancer index outperforms broader markets with 13% Q2 rebound - BioWorld MedTech
Exelixis, Inc. (EXEL) Stock Analysis: Riding the Wave of 30.60% Revenue Growth in the Biotechnology Sphere - DirectorsTalk Interviews
Stephens Upgrades Exelixis (EXEL) Stock, Raises PT - Yahoo Finance
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains? - MSN
The Zacks Analyst Blog Highlights Sprouts Farmers Market, Royal Gold, Thomson Reuters, Woodward and Exelixis - Zacks Investment Research
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - Yahoo Finance
Exelixis (EXEL) Receives Boosted Price Target as STELLAR-303 Tri - GuruFocus
EXEL: Analyst Raises Price Target for Exelixis to $50 | EXEL Stock News - GuruFocus
Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’ - BioSpace
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer - Business Wire
Exelixis Inc (EXEL) 財務データ
収益
当期純利益
現金流量
EPS
0.51%
大文字化:
|
ボリューム (24 時間):